Aller au contenu principal
2016 article

Structural and inhibitor screening studies of a fungal form of aspartate semialdehyde dehydrogenase from Cryptococcus neoformans

0Citations signalées, ce qui n’est pas une note de qualité
1Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : us. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Aspartate semialdehyde dehydrogenase (ASADH) functions at a critical junction in the aspartate biosynthetic pathway and represents a validated target for antimicrobial drug design. This enzyme catalyzes the NADPH‐dependent reductive dephosphorylation of β‐aspartyl phosphate to produce the key intermediate aspartate semialdehyde. Production of this intermediate represents the first committed step for the biosynthesis of essential amino acids in fungi and in bacteria. The absence of this enzyme in humans and other mammals will allow selective targeting of pathogenic microorganisms. We have accumulated significant structural and mechanistic information about the bacterial ASADHs, but have only limited knowledge of their fungal counterparts. The structure of a new fungal form of ASADH from Cryptococcus neoformans has been determined to 2.6 Å resolution. The overall structure of CnASADH is similar to that of its bacterial orthologs, but with some critical differences both in biological assembly and in secondary structural features that can potentially be exploited for the development of species selective drugs with selective toxicity against only certain infectious organisms. A customized fragment library has been screened against several fungal ASADHs and initial hits have been identified with inhibition constants ( K i ) in the low millimolar range. The ASADH obtained from this fungal species have shown different inhibition selectivity when compared to this enzyme from bacterial species and also differences between fungal species. Docking studies with the CnASADH structure are being used to guide the design and development of potent inhibitors. The long term goal of this project is to develop drugs that selectively target this enzyme and block the aspartate biosynthetic pathway. Support or Funding Information This work is supported by funding from the NIH (AI077720).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.

Titre Crossref
Structural and inhibitor screening studies of a fungal form of aspartate semialdehyde dehydrogenase from <i>Cryptococcus neoformans</i>
Date Crossref
01/04/2016
Éditeur
Wiley
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

  • University of Toledo Chemistry and Biochemistry pays non établi dans la notice
    Université ou école supérieure

Chemistry and Biochemistry — University of Toledo.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Probiotics and Fermented FoodsEnzyme Production and CharacterizationEnzyme Structure and Function

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.